ANAVEX LIFE SCIENCES CORP. Development Stage Enterprise, Deficit Accumulated During Development Stage (Deprecated 2015-01-31)
ANAVEX LIFE SCIENCES CORP. (AVXL) had Development Stage Enterprise, Deficit Accumulated During Development Stage (Deprecated 2015-01-31) of $59.33 million as of 2015-06-30, per its 10-Q filed 2015-08-14.
Discontinued › Notes
us-gaap:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage · last filed 2015-08-14
- 2015-06-30: Development Stage Enterprise, Deficit Accumulated During Development Stage (Deprecated 2015-01-31) $59.33M.
- 2015-03-31: Development Stage Enterprise, Deficit Accumulated During Development Stage (Deprecated 2015-01-31) $55.08M.
- 2014-12-31: Development Stage Enterprise, Deficit Accumulated During Development Stage (Deprecated 2015-01-31) $53.36M.
- 2014-09-30: Development Stage Enterprise, Deficit Accumulated During Development Stage (Deprecated 2015-01-31) $52.57M.
| Period end | Development Stage Enterprise, Deficit Accumulated During Development Stage (Deprecated 2015-01-31) |
|---|---|
| 2015-06-30 | $59.33M 10-Q · filed 2015-08-14 |
| 2015-03-31 | $55.08M 10-Q · filed 2015-05-14 |
| 2014-12-31 | $53.36M 10-Q · filed 2015-02-17 |
| 2014-09-30 | $52.57M 10-Q · filed 2015-08-14 |
| 2014-06-30 | $42.87M 10-Q · filed 2014-08-13 |
| 2014-03-31 | $41.87M 10-Q/A · filed 2014-05-30 |
| 2013-12-31 | $40.85M 10-Q · filed 2014-02-14 |
| 2013-09-30 | $41.20M 10-K · filed 2014-12-29 |
| 2013-06-30 | $38.22M 10-Q · filed 2013-08-14 |
| 2013-03-31 | $38.06M 10-Q · filed 2013-05-17 |
| 2012-12-31 | $37.96M 10-Q · filed 2013-02-14 |
| 2012-09-30 | $37.50M 10-K · filed 2013-12-30 |
| 2012-06-30 | $36.83M 10-Q · filed 2012-08-17 |
| 2012-03-31 | $32.28M 10-Q · filed 2012-05-15 |
| 2011-12-31 | $31.38M 10-Q · filed 2012-02-14 |
| 2011-09-30 | $29.20M 10-K · filed 2012-12-31 |
| 2011-06-30 | $27.78M 10-Q · filed 2011-08-12 |
| 2010-09-30 | $21.90M 10-K · filed 2011-12-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |